Swan Capital LLC Coherus Bio Sciences, Inc. Transaction History
Swan Capital LLC
- $184 Billion
- Q2 2024
A detailed history of Swan Capital LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Swan Capital LLC holds 1,300 shares of CHRS stock, worth $936. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,300Holding current value
$936% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
140Shares Held
76.8MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$8.46 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$7.63 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$7.49 Million0.53% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.19 Million0.3% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.84MShares$2.05 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $56M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...